CN102177240A - 表达载体及其方法 - Google Patents
表达载体及其方法 Download PDFInfo
- Publication number
- CN102177240A CN102177240A CN2009801361447A CN200980136144A CN102177240A CN 102177240 A CN102177240 A CN 102177240A CN 2009801361447 A CN2009801361447 A CN 2009801361447A CN 200980136144 A CN200980136144 A CN 200980136144A CN 102177240 A CN102177240 A CN 102177240A
- Authority
- CN
- China
- Prior art keywords
- seq
- sequence
- expression vector
- expression
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013604 expression vector Substances 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 title claims abstract description 44
- 230000014509 gene expression Effects 0.000 claims abstract description 76
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 69
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 37
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 30
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 27
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 27
- 239000013598 vector Substances 0.000 claims abstract description 5
- 102100036981 Interferon regulatory factor 1 Human genes 0.000 claims description 65
- 210000004027 cell Anatomy 0.000 claims description 65
- 230000004927 fusion Effects 0.000 claims description 32
- 210000004962 mammalian cell Anatomy 0.000 claims description 22
- 238000001890 transfection Methods 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 15
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 239000013612 plasmid Substances 0.000 claims description 15
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 10
- 230000002103 transcriptional effect Effects 0.000 claims description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 8
- 102000037865 fusion proteins Human genes 0.000 claims description 8
- 108020001507 fusion proteins Proteins 0.000 claims description 8
- 238000013519 translation Methods 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 230000010076 replication Effects 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 238000010276 construction Methods 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 238000013326 plasmid cotransfection Methods 0.000 claims description 2
- 230000008488 polyadenylation Effects 0.000 claims description 2
- 230000014621 translational initiation Effects 0.000 claims description 2
- 108091026890 Coding region Proteins 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 210000004507 artificial chromosome Anatomy 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 108091006020 Fc-tagged proteins Proteins 0.000 abstract 2
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 abstract 2
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 description 35
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 35
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 34
- 235000018102 proteins Nutrition 0.000 description 22
- 108010077544 Chromatin Proteins 0.000 description 19
- 210000003483 chromatin Anatomy 0.000 description 19
- 230000000694 effects Effects 0.000 description 15
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 14
- 102100040247 Tumor necrosis factor Human genes 0.000 description 14
- 239000011159 matrix material Substances 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 230000002068 genetic effect Effects 0.000 description 11
- 206010039073 rheumatoid arthritis Diseases 0.000 description 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 9
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 9
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 239000000370 acceptor Substances 0.000 description 8
- 241000699802 Cricetulus griseus Species 0.000 description 7
- 208000003456 Juvenile Arthritis Diseases 0.000 description 7
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 7
- 208000019069 chronic childhood arthritis Diseases 0.000 description 7
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 7
- 210000001672 ovary Anatomy 0.000 description 7
- 239000013600 plasmid vector Substances 0.000 description 7
- 230000006798 recombination Effects 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- 230000010354 integration Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 4
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 4
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000000299 nuclear matrix Anatomy 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000008521 reorganization Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 230000004544 DNA amplification Effects 0.000 description 3
- 230000007067 DNA methylation Effects 0.000 description 3
- 108010008165 Etanercept Proteins 0.000 description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102100029131 Retrotransposon Gag-like protein 4 Human genes 0.000 description 2
- 108700025695 Suppressor Genes Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000012212 insulator Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000726103 Atta Species 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 208000036086 Chromosome Duplication Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010022894 Euchromatin Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- OOFLZRMKTMLSMH-UHFFFAOYSA-N H4atta Chemical compound OC(=O)CN(CC(O)=O)CC1=CC=CC(C=2N=C(C=C(C=2)C=2C3=CC=CC=C3C=C3C=CC=CC3=2)C=2N=C(CN(CC(O)=O)CC(O)=O)C=CC=2)=N1 OOFLZRMKTMLSMH-UHFFFAOYSA-N 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101001094537 Homo sapiens Retrotransposon Gag-like protein 3 Proteins 0.000 description 1
- 101000699781 Homo sapiens Retrotransposon Gag-like protein 4 Proteins 0.000 description 1
- 101000699777 Homo sapiens Retrotransposon Gag-like protein 5 Proteins 0.000 description 1
- 101000699774 Homo sapiens Retrotransposon Gag-like protein 6 Proteins 0.000 description 1
- 101001073409 Homo sapiens Retrotransposon-derived protein PEG10 Proteins 0.000 description 1
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 1
- 101000801232 Homo sapiens Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 101000689689 Oryzias latipes Alpha-1A adrenergic receptor Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 101000945964 Rattus norvegicus CCAAT/enhancer-binding protein beta Proteins 0.000 description 1
- 101000924396 Rattus norvegicus Cytosol aminopeptidase Proteins 0.000 description 1
- 101001001280 Rattus norvegicus Lysosomal acid phosphatase Proteins 0.000 description 1
- 101710195674 Replication initiator protein Proteins 0.000 description 1
- 102100029146 Retrotransposon Gag-like protein 5 Human genes 0.000 description 1
- 102100029147 Retrotransposon Gag-like protein 6 Human genes 0.000 description 1
- 102100035844 Retrotransposon-derived protein PEG10 Human genes 0.000 description 1
- 102100035123 Retrotransposon-like protein 1 Human genes 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700007696 Tetrahydrofolate Dehydrogenase Proteins 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 210000000632 euchromatin Anatomy 0.000 description 1
- 230000010429 evolutionary process Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- -1 flanking region Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 150000001261 hydroxy acids Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002415 kinetochore Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000009343 monoculture Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN01941/CHE/2008 | 2008-08-12 | ||
| IN1941CH2008 | 2008-08-12 | ||
| PCT/IB2009/006517 WO2010018444A2 (fr) | 2008-08-12 | 2009-08-12 | Vecteur d'expression et son procédé |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102177240A true CN102177240A (zh) | 2011-09-07 |
Family
ID=41669395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801361447A Pending CN102177240A (zh) | 2008-08-12 | 2009-08-12 | 表达载体及其方法 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2331693A2 (fr) |
| JP (1) | JP2012506694A (fr) |
| KR (1) | KR20110044769A (fr) |
| CN (1) | CN102177240A (fr) |
| AU (1) | AU2009280913A1 (fr) |
| BR (1) | BRPI0918008A2 (fr) |
| CA (1) | CA2736580A1 (fr) |
| MX (1) | MX2011001644A (fr) |
| WO (1) | WO2010018444A2 (fr) |
| ZA (1) | ZA201101882B (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103740756A (zh) * | 2013-12-25 | 2014-04-23 | 中国农业大学 | 一种可调控删除的非病毒游离载体及其构建方法 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010049777A1 (fr) * | 2008-10-28 | 2010-05-06 | Avesthagen Limited | Vecteur d’expression et procédés |
| WO2011015924A2 (fr) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | Vecteurs et composés pour expression du trastuzumab de recombinaison |
| WO2011015916A2 (fr) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | Vecteurs et composés pour expression dinfliximab recombinant |
| WO2011015918A2 (fr) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | Vecteurs et composés pour l'expression de cetuximab de recombinaison |
| WO2011015917A2 (fr) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | Vecteurs et composés pour expression de tnk-tpa recombinant (tenecteplase) |
| GB201213117D0 (en) * | 2012-07-24 | 2012-09-05 | Ucl Business Plc | Transgene expression |
| WO2019057774A1 (fr) * | 2017-09-19 | 2019-03-28 | Deutsches Krebsforschungszentrum | Vecteurs d'adn non intégrants pour la modification génétique de cellules |
| ES2821655T3 (es) * | 2017-09-19 | 2021-04-27 | Deutsches Krebsforsch | Vectores de ADN no integrantes para la modificación genética de células |
| WO2019088257A1 (fr) * | 2017-11-02 | 2019-05-09 | 国立大学法人鳥取大学 | Procédé de production à haut rendement d'une protéine à l'aide d'un vecteur de chromosome artificiel de mammifère |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2123593C (fr) * | 1992-09-15 | 2000-03-14 | Craig A. Smith | Methode de traitement de l'inflammation dependante du tnf a l'aide d'antagonistes du facteur de necrose tumorale |
| US7541512B2 (en) * | 2001-03-30 | 2009-06-02 | Synageva Biopharma Corp. | Avians containing a lysozyme promoter transgene |
| ATE514783T1 (de) * | 2003-11-12 | 2011-07-15 | Schering Corp | Plasmidsystem zur expression mehrerer gene |
-
2009
- 2009-08-12 AU AU2009280913A patent/AU2009280913A1/en not_active Abandoned
- 2009-08-12 BR BRPI0918008A patent/BRPI0918008A2/pt not_active Application Discontinuation
- 2009-08-12 KR KR1020117005118A patent/KR20110044769A/ko not_active Application Discontinuation
- 2009-08-12 JP JP2011522562A patent/JP2012506694A/ja active Pending
- 2009-08-12 MX MX2011001644A patent/MX2011001644A/es not_active Application Discontinuation
- 2009-08-12 CA CA2736580A patent/CA2736580A1/fr not_active Abandoned
- 2009-08-12 WO PCT/IB2009/006517 patent/WO2010018444A2/fr active Application Filing
- 2009-08-12 CN CN2009801361447A patent/CN102177240A/zh active Pending
- 2009-08-12 EP EP09806504A patent/EP2331693A2/fr not_active Withdrawn
-
2011
- 2011-03-11 ZA ZA2011/01882A patent/ZA201101882B/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103740756A (zh) * | 2013-12-25 | 2014-04-23 | 中国农业大学 | 一种可调控删除的非病毒游离载体及其构建方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010018444A3 (fr) | 2010-05-14 |
| BRPI0918008A2 (pt) | 2018-07-17 |
| AU2009280913A1 (en) | 2010-02-18 |
| ZA201101882B (en) | 2012-07-25 |
| WO2010018444A2 (fr) | 2010-02-18 |
| KR20110044769A (ko) | 2011-04-29 |
| EP2331693A2 (fr) | 2011-06-15 |
| MX2011001644A (es) | 2011-10-06 |
| CA2736580A1 (fr) | 2010-02-18 |
| JP2012506694A (ja) | 2012-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102177240A (zh) | 表达载体及其方法 | |
| MX2011002706A (es) | Tornillo radiolucido con marcador radiopaco. | |
| CN102165060B (zh) | 新的调控组件 | |
| AU2008339985C1 (en) | Mammalian expression vector | |
| Boscolo et al. | Simple scale-up of recombinant antibody production using an UCOE containing vector | |
| CN109136261B (zh) | 人源化cd28基因改造动物模型的制备方法及应用 | |
| JPH08502884A (ja) | 哺乳動物細胞における複シストロンベクター系を用いるヘテロダイマーｐｄｇｆ−ａｂの調製 | |
| CN101437946A (zh) | 选择高水平表达蛋白质的宿主细胞 | |
| CN103038352B (zh) | 用于增强基因表达的新型基因间元件 | |
| CN102257141A (zh) | 表达载体和其加工方法 | |
| CN103492577B (zh) | 用于动物细胞的表达载体 | |
| CA2611946C (fr) | Vecteur d'expression et procedes de production de niveaux eleves de proteines | |
| CN103305504B (zh) | 在仓鼠细胞中定点重组的组合物和方法 | |
| JPH05503015A (ja) | 哺乳類発現ベクター | |
| CN101245106B (zh) | 抗vegf受体单克隆抗体及其制备方法和应用 | |
| CN103865931B (zh) | 具有提高外源基因表达活性的dna元件 | |
| CN112899238A (zh) | 基于RNA-m6A修饰水平的化合物筛选细胞模型及其构建与应用 | |
| IMAMURA et al. | The murine interleukin-5 receptor α-subunit gene: characterization of the gene structure and chromosome mapping | |
| KR20100097123A (ko) | 신규한 재조합 서열 | |
| CN103865947A (zh) | 一种包含弱化的sv40启动子/二氢叶酸还原酶表达元件的真核表达载体及其构建方法 | |
| CN1717489B (zh) | 真核细胞中的序列特异性dna重组 | |
| CN101541959A (zh) | 用于增加转录的基质附着区（mar）及其应用 | |
| CN104975018A (zh) | 一种新型增强子及其应用 | |
| WO2011015916A2 (fr) | Vecteurs et composés pour expression dinfliximab recombinant | |
| CN103339255A (zh) | 蛋白质的生产方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110907 |